Updated on 6 August 2015
Oncology drug pipeline is far larger than any other therapy area across the pharmaceutical industry, with 6,484 products in active development
Singapore: The oncology drug pipeline is far larger than any other therapy area across the pharmaceutical industry, with 6,484 products in active development across all indications, suggesting significant opportunities for new market entries, according to business intelligence provider GBI Research.
A new report states that of the pipeline of oncology products in development, the majority are in the early stages, with 2,937, equivalent to 45% of the total pipeline, at the preclinical stage, and 1,591, or 25%, at the Discovery stage.
Mr Dominic Trewartha, managing analyst for GBI Research, commented that the oncology therapeutic pipeline is highly diverse, containing a broad array of mechanisms of action.
This contrasts heavily with the market, which predominantly consists of chemotherapy, hormonal and central nervous system targets.
Mr Trewartha commented, "Signal transduction targets, cancer antigens and receptor tyrosine kinases are the three most common categories of pipeline product across all stages of development. In addition, there are a large number of first-in-class products in development for oncology, with 2,084 across all stages, and 46% of pipeline products have a disclosed target. This indicates a very high level of investment in the development of innovative products in this therapy area."